Drugs / Descovy
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Descovy | — | 2016-04-21 | europa.eu ↗ |
| Approved | US (FDA) | DESCOVY | — | 2016-04-04 | fda.gov ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07210528 | Jun 2025 → Mar 2026 overdue | Alzheimer disease | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04051970 | Nov 2019 → Jun 2022 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Terminated | No outcome recorded Stop: Enrollment |
| Phase 42 trials | ||||||
| Phase 4 | NCT05528653 | Jul 2022 → Jul 2024 | — | Vivent Health | Completed | No outcome recorded |
| Phase 4 | NCT04782180 | Feb 2022 → Nov 2024 | HIV infectious disease, substance-related disorder | University of Miami | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2/3 | NCT04742491 Background | Mar 2021 → Aug 2024 | — | HIV Prevention Trials Network | Completed | No outcome recorded |
| Phase 3 | NCT05378399 Background | Dec 2022 → Feb 2026 | HIV infectious disease, substance-related disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02486133 Comparator | Jul 2015 → May 2018 | HIV infectious disease | Technical University of Munich | Completed | No outcome recorded |
Press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Descovy | “one daily tablet of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) or one daily tablet of Truvada (emtricitabine 200 mg and tenofovir disoproxil...” NCT04742491 ↗6“TDF/XTC Gé or Descovy®” NCT04051970 ↗ |
| Known as | FTC/TAF | “one daily tablet of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) or one daily tablet of Truvada (emtricitabine 200 mg and tenofovir disoproxil...” NCT04742491 ↗ |
| Route | Oral | “daily Descovy tab by mouth” NCT04782180 ↗ |